The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Emerging third-generation BTK-targeted therapies for CLL: overcoming BTK resistance
Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, discusses the promise of third-generation agents for chronic lymphocytic leukemia (CLL), including the BTK inhibitor nemtabrutinib and the BTK degrader tacabrutideg, to overcome resistance that occurs with covalent BTK inhibitors. Dr Ghia also highlights the importance of fixed-duration treatment to prevent patients from becoming refractory to drugs. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
